SPK 843

Drug Profile

SPK 843

Alternative Names: IB 643; SPA S 752; SPA S 753; SPA S 843

Latest Information Update: 19 Jan 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SPA
  • Developer Kaken Pharmaceutical; SPA
  • Class Antifungals
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Mycoses

Most Recent Events

  • 19 Jan 2011 No development reported - Phase-II for Mycoses in Japan (IV)
  • 28 May 2008 Discontinued - Preclinical for Mycoses in Italy (IV)
  • 28 May 2008 Pharmacodynamics data from preclinical trials in Mycoses released by Kaken Pharmaceutical Co. ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top